InflaRx NV (STU:IF0) Short Interest


STU:IF0 InflaRx NV STU:IF0
30 GF Score
Price €1.68
! 5 Warning Signs
View Full Analysis

What is InflaRx NV Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:IF0 vs IRD, NAUT, RGNX: Short Interest Comparison

For the Biotechnology subindustry, InflaRx NV's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Short Interest distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Short Interest falls into.


STU:IF0
30GF Score
InflaRx NV STU:IF0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV Business Description

Other Exchanges IFRX:USAIF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
30GF Score

Get the complete analysis for STU:IF0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.68
Price